FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington,	D.C.	20549	

•

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average bu	rden
hours per response:	0.5
	OMB Number: Estimated average bu

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Troendle August J.</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol Medpace Holdings, Inc. [ MEDP ]									5. Relationship of Repo (Check all applicable) X Director			rting Person(s) to I					
(Last) (First) (Middle) C/O MEDPACE HOLDINGS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 11/17/2023									X	Office belov	•	e Othe below		(specify				
5375 MEDPACE WAY						4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street) CINCINNATI OH 45227																	X Form filed by One Reporting Person  Form filed by More than One Reporting  Person						
(City)	(	State)	(Z	ip)		Rule 10b5-1(c) Transaction Indication																	
								Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
			Table	I - N	lon-Deriva	tive	Sec	curit	ties	Acc	quire	ed, D	isposed o	of, or I	Benefic	ially	/ Own	ed					
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 au			and 5) Securities Beneficially Owned Following			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
							(	Code	v	Amount (A) or (D) Price		Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)					
Common Stock			11/17/202	23				S <sup>(1)</sup>		50,000	D	\$273.91 <sup>(2)</sup>		5,789,947		I		By Medpace Investors, LLC <sup>(3)</sup>					
Common Stock			11/20/2023					S <sup>(1)</sup>		50,000	D	\$275.4	5 <sup>(4)</sup>	5,739,947		I		By Medpace Investors, LLC <sup>(3)</sup>					
Common Stock															806,643		6,643	5,643 D					
			Tak	ole I	l - Derivati e.a pu)								posed of , converti				Owne	d					
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Gecurity or Exercise (Month/Day/Year) if any		Deemed cution Date,	4. Trans Code 8)	Transaction Code (Instr. 8)  Derivative Securitit Acquire (A) or Dispose of (D) (Instr. 3, and 5)		nber ative ities red sed 3, 4	6. D. Exp (Mo	ate Exi iration nth/Da	Expiration	7. Tit Amo Secu Unde Deriv Secu 3 and	le and unt of rities erlying vative rity (Instr.	nt er		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)					

## **Explanation of Responses:**

- 1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period.
- 2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$272.00 to \$279.85. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.
- 3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 4. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$272.00 to \$277.805. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request.

/s/ Stephen P. Ewald,

Attorney-in-Fact for August J. 11/21/2023

**Troendle** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.